IDEMIA Awarded iBeta Certification for its Biometric Liveness Detection Solution
IDEMIA, the global leader in Augmented Identity, has announced that its liveness detection technology has been awarded Level 1 and Level 2 certification by iBeta, an independent third-party tester, in accordance with the ISO/IEC 30107-3 standards.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200211005642/en/
(Photo: Business Wire)
Testing was conducted by independent quality assurance provider, iBeta, and completed in December 2019. The testing method simulated the enrollment of a user in a biometric authentication system, where legitimate users consented to photos and videos of their likeness being used in attempts to spoof the system (Level 1 testing), and also the use of more sophisticated artefacts like silicone, latex, and plastic masks (Level 2 testing).
The testers were not able to gain access to the system using any of the presentation attacks, meaning that IDEMIA’s liveness detection technology achieved an attack presentation classification error rate (APCER) of 0%.
IDEMIA’s SmartBio® and WebBioServer® SDKs both leverage the liveness detection technology, which enables clients to offer multi-channel identity verification solutions via Android and iOS mobile apps, or through web browsers on either desktop or mobile devices.
Increasingly, banks, mobile operators, and other service providers are under pressure to offer their customers a remote, digital onboarding journey. The mass adoption of mobile devices with biometric sensors, combined with widespread broadband coverage worldwide, make this transformation possible.
However, remote onboarding presents an opportunity for fraudsters to open an account using a presentation attack, which is when spoofed biometric information is presented to a biometric sensor. Common presentation attacks include a fake image or video of a legitimate customer, fake silicon or gelatin masks, and fake fingerprints.
Presentation attack detection (PAD) is vitally important for service providers that want to secure their digital onboarding processes while reducing the impact of fraud. PAD also helps service providers comply with anti-money laundering (AML) and counter-terrorism financing (CTF) regulations, which may result in hefty penalties from regulators should their processes be deemed inadequate for accurately combatting fraud.
To date, IDEMIA is one of just two companies worldwide to have achieved Level 2 Liveness Detection certification.
“At IDEMIA, we pride ourselves in our ability to create cutting-edge biometric solutions capable of streamlining a user’s digital journey and combatting fraud,” said Muzaffar Khokhar, Executive Vice President, Digital Business Unit, IDEMIA. “This independent accreditation proves our expertise, and will enable us to provide a more complete portfolio of onboarding and anti-fraud solutions for our clients across the globe.”
IDEMIA’s liveness detection technology is available through the SmartBio® and WebBioServer® SDKs, and is part of the company’s innovative digital identity platform. The platform is a powerful solution for enterprises and service providers to identify, manage, and authenticate digital identities in a secure, trusted, and convenient way.
iBeta is the only NIST NVLAP accredited biometrics testing lab (NVLAP testing Lab Code 200962-0). iBeta developed a quality management system and biometrics test procedures that are independently audited by NVLAP (National Voluntary Laboratory Accreditation Program) in a comprehensive technical evaluation in accordance with the recognized International Standard ISO/IEC 17025:2017.
View the IDEMIA PAD Level 1 Confirmation Letter (PDF)
View the IDEMIA PAD Level 2 Confirmation Letter (PDF)
For more information on IDEMIA’s digital identity platform and other digital identity technology, visit https://www.idemia.com/digital-identity-enterprises
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With 13,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200211005642/en/
Contact information
Press
PR Agency: Havas Paris
Irina Pungaru
+33 6 13 02 34 76
idemia@havas.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
Incyte Japan Announces Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer22.12.2025 08:42:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of advanced squamous cell carcinoma of the anal canal (SCAC). "Today's approval marks a significant milestone for patients with advanced anal cancer in Japan – the MHLW’s approval of Zynyz as the first and only first-line treatment for SCAC," said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan G.K. "By offering combination therapy with chemotherapy, Zynyz provides a vital new path forward for patients facing this challenging disease, addressing a significant unmet need in cancer care for patients with SCAC and their families." The approval was based on data from the Phase 3 POD1UM-303/InterAACT2 trial evaluating Zynyz in combination with platinum-based chemotherapy (carboplatin-paclitaxel) in adult patients with metastatic or inoperable
GBC AG Analyst Coverage Report on Mexedia S.p.A. Società Benefit Completed and Published22.12.2025 08:30:00 CET | Press Release
Regulatory News: Mexedia S.p.A. Società Benefit (Euronext Growth Paris: ALMEX, ISIN IT0005450819) (“Mexedia” or the “Company”) informs that the analyst coverage report prepared by GBC AG – one of the leading independent financial research firms in Germany –, developed within an issuer-sponsored research framework, has been completed and is now publicly available. The report follows the re-initiation of analyst coverage by GBC AG previously communicated by the Company and is based exclusively on publicly available information. The content, assumptions and conclusions of the report are solely attributable to the analyst. The GBC AG analyst coverage report is available on the Company’s official website at the following address: https://mexedia.com/en/financial-statements-and-reports/ and on the analyst’s website. Daniel Gilcher, Chief Financial Officer of Mexedia S.p.A. Società Benefit, stated: “The completion and publication of the analyst coverage report by GBC AG represents the conclus
Hisense Joins HEVC Advance Patent Pool22.12.2025 03:06:00 CET | Press Release
Access Advance LLC, the global leader in video codec patent pool licensing, today announced that Hisense Group Holdings Co., Ltd. has joined the HEVC Advance Patent Pool as a Licensee. Hisense joins the recent additions to the Access Advance patent pools, including Xiaomi, MSI, Transsion, and expanded relationships with Huawei, HP and Sharp. Hisense, headquartered in Qingdao, China, is one of the world's largest television manufacturers, with a global presence spanning Asia, Europe, the Americas, and beyond. The company's products reach consumers in more than 160 countries and regions worldwide. "We are pleased to welcome Hisense to the HEVC Advance Patent Pool," said Peter Moller, CEO of Access Advance. "This agreement is the result of extensive engagement between our teams over a considerable period of time. Hisense's decision to join the pool reflects a recognition that transparent, efficient licensing solutions benefit both innovators and implementers across the video technology ec
Textron Aviation Defense Secures First Contract to Deliver Beechcraft T-6 Texan II Integrated Training System to Japan22.12.2025 02:00:00 CET | Press Release
Textron Aviation Defense LLC, a Textron Inc. (NYSE:TXT) company, today announced that the company has finalized its first contract to deliver the Beechcraft T-6JP Texan II integrated training system to Japan’s Air Self-Defense Force (JASDF), in coordination with Kanematsu Corporation. The initial contract includes two Beechcraft T-6JP Texan II aircraft and instructor pilot and aircraft maintainer training materials. Deliveries of the first two aircraft are scheduled for 2029, with additional contracts anticipated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251221925354/en/ The Beechcraft T-6 Texan II is designed and manufactured by Textron Aviation Defense LLC, a wholly owned subsidiary of Textron Aviation Inc. “This contract marks a pivotal step in strengthening Japan’s next-generation pilot training capabilities,” said Travis Tyler, president and CEO, Textron Aviation Defense. “We’re honored to support the Japan Air Se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
